Scarica l'app Stockscreener
0.9486
16.19%
0.1322
Dopo l'orario di chiusura:
.96
0.0114
+1.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.8164
Aprire:
$0.88
Volume 24 ore:
2.35M
Relative Volume:
3.12
Capitalizzazione di mercato:
$21.23M
Reddito:
-
Utile/perdita netta:
$-38.85M
Rapporto P/E:
-0.3278
EPS:
-2.8936
Flusso di cassa netto:
$-44.99M
1 W Prestazione:
+25.78%
1M Prestazione:
+33.23%
6M Prestazione:
-22.88%
1 anno Prestazione:
-44.20%
Intervallo 1D:
$0.8711
$1.00
Intervallo di 1 settimana:
$0.6714
$1.00
Portata 52W:
$0.63
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Nome
Citius Pharmaceuticals Inc
Settore
Industria
Telefono
(908) 967-6676
Indirizzo
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.9486 | 18.27M | 0 | -38.85M | -44.99M | -2.8936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
CTXR Should I Buy - Intellectia AI
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Citius Pharmaceuticals CEO Leonard Mazur pursues growth through regulatory partnerships and rare disease therapies - Traders Union
CTXR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Movement Recap: Is Citius Pharmaceuticals Inc benefiting from interest rate changesJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Citius Pharmaceuticals Secures $3.8M Via Net Operating Loss Program - New Jersey Business Magazine
Citius Pharmaceuticals (CTXR) Secures $3.8M Through NJ Tax Progr - GuruFocus
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PR Newswire
Market Pulse: Can Citius Pharmaceuticals Inc lead its sector in growthJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Resistance Check: Can GRNQ maintain sales growthWeekly Market Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Patterns Watch: Will USAC outperform small cap indexesWeekly Loss Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Activity Recap: How does USBPRA perform in inflationary periodsBull Run & Weekly Momentum Stock Picks - baoquankhu1.vn
Analyst Downgrade: Is NVGS forming bullish engulfing patternsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive
Dip Buying: Will Citius Pharmaceuticals Inc benefit from rate cutsJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
CVI and Heights disclose 9.9% Citius Pharmaceuticals (CTXR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
FOMO Trade: Is now the right time to enter MAPSMarket Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Can Citius Pharmaceuticals Inc. stock continue upward trendWall Street Watch & Free High Return Stock Watch Alerts - mfd.ru
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know - Benzinga
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk - TipRanks
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CTXR: First revenue of $3.9M from LYMPHIR launch, narrowing net loss and strong pipeline progress - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Pharmaceuticals reports first revenue of $3.9 mln - TradingView
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire
Risk Check: Should you buy the dip on ImmuCell CorporationWeekly Trend Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Market Review: Is Citius Pharmaceuticals Inc a cyclical or defensive stockPortfolio Performance Report & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st
Does Citius Pharmaceuticals Inc. align with a passive investing strategyTrade Volume Report & Daily Technical Forecast Reports - mfd.ru
Aug PostEarnings: Is IMRN subject to activist investor interest2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz
Citius Oncology Expands International Distribution of LYMPHIR™ t - GuruFocus
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
Is Citius Pharmaceuticals Inc. stock positioned well for digital economy2025 Performance Recap & Daily Entry Point Trade Alerts - mfd.ru
What is the earnings history of Citius Pharmaceuticals IncJuly 2025 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Risk Check: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
VIX Spike: Is Citius Pharmaceuticals Inc a potential multi baggerJuly 2025 WrapUp & Smart Allocation Stock Tips - baoquankhu1.vn
Weekly Earnings: Can Howard Hughes Holdings Inc deliver consistent EPS growthEarnings Overview Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Citius Pharmaceuticals announces registered direct offering of $15.8 million - MSN
Geopolitics Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesTrade Performance Summary & Short-Term Trading Alerts - baoquankhu1.vn
Citius Pharmaceuticals Inc Azioni (CTXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):